Beyond Therapies
We have breadth and depth in clinical, scientific and commercial understanding. We conduct research for clinically complex and specialist indication areas, alongside general, primary care indications. Our top therapy areas to work in are:
Oncology
Neurology
Cardiology
Immunology
Oncology
Neurology
Cardiology
Immunology
For decades, clients have returned to us with their business challenges in the oncology space.
Oncology is an evolving therapy area, with advances in disease understanding, new technology mechanisms, new targets and greater fragmentation of patient cohorts – all of which contribute to the complexity of treatment.
We understand that pharma companies require a strategic research team who not only keeps abreast of the changes in the marketplace, conference activity and latest thinking, but who also has…
- A deep appreciation of the science
- An understanding of the market dynamics
- A technical understanding of the stakeholders involved
- Appropriate recruitment strategies
- Senior-level interpretation to deliver meaningful and actionable insights
We have a solid reputation working in this complex and fast-moving space. With around 30% of our business being in oncology, we have an internal team of senior experts who work on oncology engagements and take insights further to ensure we continue to exceed our clients’ expectations.
If you would like to find out more about how we can support your pre-launch or post-launch oncology needs or how you could become a strategic partner, get in touch with our Research Directors: Lindsay, Siobhan or Paula. We support through the scoping out of initial needs to research design, analysis and beyond.
For more information on our thoughts and highlights from ASCO 2024 click below.
To find out what's in store at ESMO 2024 click below.
Check out our deep dive case study click below.
Lung Cancer Awareness Month 2024
It’s Lung Cancer Awareness Month, which made us reflect on our recent interactions with patients …. Understanding the Journey of NSCLC Patients: A Call to Action In our extensive work with non-small cell lung cancer (NSCLC), we’ve learned one undeniable truth: there...
Elevating Excellence: Expanding Our Oncology Team
Oncology has always been a key area of focus for us. As the demand for our oncology expertise continues to surge, we are thrilled to announce the expansion of our devoted team. Within the fabric of our expanding team, a key objective is to establish a dedicated group...
Navigating 2024’s Oncology Hot Topics
As we embark on a new year, our oncology team has been busy crafting predictions to guide us through 2024. Continue reading to discover the key trends and game-changers our team have selected. Will it be a green light for CAR-T ambitions, or a U-turn? Stepping into...
Top takeouts from ESMO 2023
Last week, our Research Directors, Siobhan Davies and Lindsay Widger, landed back in the UK from the ESMO Congress 2023 in Madrid. The conference brought together likeminded passionate professionals in oncology to discuss and digest the very latest developments. ESMO...
ESMO Congress Madrid 2023: What’s in store?
ESMO 2023 Madrid beckons, in just over a week (20th -24th October). Our Research Directors, Lindsay Widger and Siobhan Davies, will be in attendance reporting back on the hottest topics and connecting with like-minded oncology experts to discuss the implications as...
ASCO 2023: Our key themes
A few weeks ago, we attended the ASCO Annual Meeting which brought the latest oncology developments. The meeting provides an exceptional opportunity to connect with one of the largest, most diverse audiences in global cancer care and we were extremely proud to be a...
Neoadjuvant Chemo-IO – a new standard for resectable NSCLC?
12 months ago, at ESMO 2021, the oncology community was asked, “Are we ready to consider chemotherapy + checkpoint inhibitor as the preferred option in the neoadjuvant setting?”. At that time, 71% felt the available efficacy data was not sufficient to implement...
Expert insights into future opportunities in immuno-oncology
It is widely accepted that the use of immunotherapy agents has been one of the major advances in oncology over recent years. But what further changes can we expect as the area develops in the next few years, and what does that mean for pharma? To look further into...
Oncology Trends, Views and Perspectives from Beyond Blue
What are the leading oncology issues and drug development trends, outside of reimbursement/drug access? What is the impact of COVID–19 across oncology? How can we use market research methods to maximise stakeholder insights on future oncology drug development,...
We have extensive expertise in neurology, across many different indications such as Multiple Sclerosis, Parkinson’s Disease, Neuromyelitis Optica Spectrum Disorder, Myasthenia Gravis and Huntington’s Disease.
Our knowledge and experience ensures we deliver extra layers of confidence and insight to our high-quality research.
Recent projects have included:
- Patient journey and TPP assessment in Myasthenia Gravis
- Clinical trial scenario testing in Parkinson’s Disease
- Lexicon research in Huntington’s Disease
- Patient chart audit in NMOSD
See our latest thinking for more insights!
For decades, clients have returned to us with their business challenges in the oncology space.
Oncology is an evolving therapy area, with advances in disease understanding, new technology mechanisms, new targets and greater fragmentation of patient cohorts – all of which contribute to the complexity of treatment.
We understand that pharma companies require a strategic research team who not only keeps abreast of the changes in the marketplace, conference activity and latest thinking, but who also has…
- A deep appreciation of the science
- An understanding of the market dynamics
- A technical understanding of the stakeholders involved
- Appropriate recruitment strategies
- Senior-level interpretation to deliver meaningful and actionable insights
We have a solid reputation working in this complex and fast-moving space. With around 30% of our business being in oncology, we have an internal team of senior experts who work on oncology engagements and take insights further to ensure we continue to exceed our clients’ expectations.
If you would like to find out more about how we can support your pre-launch or post-launch oncology needs or how you could become a strategic partner, get in touch with our Research Directors: Lindsay, Siobhan or Paula. We support through the scoping out of initial needs to research design, analysis and beyond.
For more information on our thoughts and highlights from ASCO 2024 click below.
To find out what's in store at ESMO 2024 click below.
Check out our deep dive case study click below.
Lung Cancer Awareness Month 2024
It’s Lung Cancer Awareness Month, which made us reflect on our recent interactions with patients …. Understanding the Journey of NSCLC Patients: A Call to Action In our extensive work with non-small cell lung cancer (NSCLC), we’ve learned one undeniable truth: there...
Elevating Excellence: Expanding Our Oncology Team
Oncology has always been a key area of focus for us. As the demand for our oncology expertise continues to surge, we are thrilled to announce the expansion of our devoted team. Within the fabric of our expanding team, a key objective is to establish a dedicated group...
Navigating 2024’s Oncology Hot Topics
As we embark on a new year, our oncology team has been busy crafting predictions to guide us through 2024. Continue reading to discover the key trends and game-changers our team have selected. Will it be a green light for CAR-T ambitions, or a U-turn? Stepping into...
Top takeouts from ESMO 2023
Last week, our Research Directors, Siobhan Davies and Lindsay Widger, landed back in the UK from the ESMO Congress 2023 in Madrid. The conference brought together likeminded passionate professionals in oncology to discuss and digest the very latest developments. ESMO...
ESMO Congress Madrid 2023: What’s in store?
ESMO 2023 Madrid beckons, in just over a week (20th -24th October). Our Research Directors, Lindsay Widger and Siobhan Davies, will be in attendance reporting back on the hottest topics and connecting with like-minded oncology experts to discuss the implications as...
ASCO 2023: Our key themes
A few weeks ago, we attended the ASCO Annual Meeting which brought the latest oncology developments. The meeting provides an exceptional opportunity to connect with one of the largest, most diverse audiences in global cancer care and we were extremely proud to be a...
Neoadjuvant Chemo-IO – a new standard for resectable NSCLC?
12 months ago, at ESMO 2021, the oncology community was asked, “Are we ready to consider chemotherapy + checkpoint inhibitor as the preferred option in the neoadjuvant setting?”. At that time, 71% felt the available efficacy data was not sufficient to implement...
Expert insights into future opportunities in immuno-oncology
It is widely accepted that the use of immunotherapy agents has been one of the major advances in oncology over recent years. But what further changes can we expect as the area develops in the next few years, and what does that mean for pharma? To look further into...
Oncology Trends, Views and Perspectives from Beyond Blue
What are the leading oncology issues and drug development trends, outside of reimbursement/drug access? What is the impact of COVID–19 across oncology? How can we use market research methods to maximise stakeholder insights on future oncology drug development,...
We have extensive expertise in neurology, across many different indications such as Multiple Sclerosis, Parkinson’s Disease, Neuromyelitis Optica Spectrum Disorder, Myasthenia Gravis and Huntington’s Disease.
Our knowledge and experience ensures we deliver extra layers of confidence and insight to our high-quality research.
Recent projects have included:
- Patient journey and TPP assessment in Myasthenia Gravis
- Clinical trial scenario testing in Parkinson’s Disease
- Lexicon research in Huntington’s Disease
- Patient chart audit in NMOSD